메뉴 건너뛰기




Volumn 93, Issue 5, 2006, Pages 453-462

Indications of G-CSF administration in hematologic disorders;Indications des facteurs de croissance granulocytaires en hématologie

Author keywords

Acute leukemia; Aplastic anemia; Granulocyte colony stimulating factor; Hematopoietic stem cell; Lymphoma; Myelodysplastic syndrome; Neutropenia

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

EID: 33745312179     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (6)

References (39)
  • 1
    • 0029780711 scopus 로고    scopus 로고
    • Molecular analysis of the granulocyte colony-stimulating factor receptor
    • Avalos BR. Molecular analysis of the granulocyte colony-stimulating factor receptor. Blood 1996; 88: 761-77.
    • (1996) Blood , vol.88 , pp. 761-777
    • Avalos, B.R.1
  • 2
    • 0028000668 scopus 로고
    • Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization
    • Lieschke GJ, Grail D, Hodgson G, Metcalf D, Stanley E, Cheers C, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994; 84: 1737-46.
    • (1994) Blood , vol.84 , pp. 1737-1746
    • Lieschke, G.J.1    Grail, D.2    Hodgson, G.3    Metcalf, D.4    Stanley, E.5    Cheers, C.6
  • 3
    • 0026667676 scopus 로고
    • Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial
    • Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wilkinson PM, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80: 1430-6.
    • (1992) Blood , vol.80 , pp. 1430-1436
    • Pettengell, R.1    Gurney, H.2    Radford, J.A.3    Deakin, D.P.4    James, R.5    Wilkinson, P.M.6
  • 4
    • 8244221002 scopus 로고    scopus 로고
    • Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: Factors influencing chemotherapy administration
    • Groupe d'Etude des Lymphomes de l'Adulte
    • Gisselbrecht C, Haioun C, Lepage E, Bastion Y, Tilly H, Bosly A, et al. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. Leuk Lymphoma 1997; 25: 289-300.
    • (1997) Leuk Lymphoma , vol.25 , pp. 289-300
    • Gisselbrecht, C.1    Haioun, C.2    Lepage, E.3    Bastion, Y.4    Tilly, H.5    Bosly, A.6
  • 5
    • 0030964191 scopus 로고    scopus 로고
    • Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma
    • Zinzani PL, Pavone E, Storti S, Moretti L, Fattori PP, Guardigni L, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997; 89: 3974-9.
    • (1997) Blood , vol.89 , pp. 3974-3979
    • Zinzani, P.L.1    Pavone, E.2    Storti, S.3    Moretti, L.4    Fattori, P.P.5    Guardigni, L.6
  • 6
    • 0042914721 scopus 로고    scopus 로고
    • CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma
    • Doorduijn JK, van der Holt B, van Imhoff GW, van der Hem KG, Kramer MH, van Oers MH, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 3041-50.
    • (2003) J Clin Oncol , vol.21 , pp. 3041-3050
    • Doorduijn, J.K.1    Van Der Holt, B.2    Van Imhoff, G.W.3    Van Der Hem, K.G.4    Kramer, M.H.5    Van Oers, M.H.6
  • 7
    • 10344230139 scopus 로고    scopus 로고
    • Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: A nationwide study
    • Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004; 22: 4302-11.
    • (2004) J Clin Oncol , vol.22 , pp. 4302-4311
    • Lyman, G.H.1    Dale, D.C.2    Friedberg, J.3    Crawford, J.4    Fisher, R.I.5
  • 8
    • 3042813710 scopus 로고    scopus 로고
    • Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL
    • Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104: 626-33.
    • (2004) Blood , vol.104 , pp. 626-633
    • Pfreundschuh, M.1    Trumper, L.2    Kloess, M.3    Schmits, R.4    Feller, A.C.5    Rudolph, C.6
  • 9
    • 3242802160 scopus 로고    scopus 로고
    • Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL
    • Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634-41.
    • (2004) Blood , vol.104 , pp. 634-641
    • Pfreundschuh, M.1    Trumper, L.2    Kloess, M.3    Schmits, R.4    Feller, A.C.5    Rube, C.6
  • 10
    • 0037313173 scopus 로고    scopus 로고
    • Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma
    • Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003; 21: 514-9.
    • (2003) J Clin Oncol , vol.21 , pp. 514-519
    • Vose, J.M.1    Crump, M.2    Lazarus, H.3    Emmanouilides, C.4    Schenkein, D.5    Moore, J.6
  • 11
    • 16444377541 scopus 로고    scopus 로고
    • Pegfilgrastrim supports delivery of CHOP-R chemotherapy administered every 14 days: A randomized phase II study
    • Lopez A, Fernandez de Sevilla A, Castaigne S, Greil R, Sierra J, Sanchez J, et al. Pegfilgrastrim supports delivery of CHOP-R chemotherapy administered every 14 days: a randomized phase II study. Blood 2004; 104: 904a.
    • (2004) Blood , vol.104
    • Lopez, A.1    Fernandez De Sevilla, A.2    Castaigne, S.3    Greil, R.4    Sierra, J.5    Sanchez, J.6
  • 12
    • 0043248410 scopus 로고    scopus 로고
    • A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer
    • Siena S, Piccart MJ, Holmes FA, Glaspy J, Hackett J, Renwick JJ. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep 2003; 10: 715-24.
    • (2003) Oncol Rep , vol.10 , pp. 715-724
    • Siena, S.1    Piccart, M.J.2    Holmes, F.A.3    Glaspy, J.4    Hackett, J.5    Renwick, J.J.6
  • 13
    • 0037567428 scopus 로고    scopus 로고
    • Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease
    • Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-95.
    • (2003) N Engl J Med , vol.348 , pp. 2386-2395
    • Diehl, V.1    Franklin, J.2    Pfreundschuh, M.3    Lathan, B.4    Paulus, U.5    Hasenclever, D.6
  • 14
    • 16444384560 scopus 로고    scopus 로고
    • Pegfilgrastim supports delivery of BEACOPP chemotherapy administered every 14 days
    • Engert A, Doehner H, Ho AD, Schmitz N, Bredenfeld H, Hoelzer D, et al. Pegfilgrastim supports delivery of BEACOPP chemotherapy administered every 14 days. Blood 2004; 104: 370a.
    • (2004) Blood , vol.104
    • Engert, A.1    Doehner, H.2    Ho, A.D.3    Schmitz, N.4    Bredenfeld, H.5    Hoelzer, D.6
  • 15
    • 0029067674 scopus 로고
    • Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: A randomized phase III trial
    • Ottmann OG, Hoelzer D, Gracien E, Ganser A, Kelly K, Reutzel R, et al. Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood 1995; 86: 444-50.
    • (1995) Blood , vol.86 , pp. 444-450
    • Ottmann, O.G.1    Hoelzer, D.2    Gracien, E.3    Ganser, A.4    Kelly, K.5    Reutzel, R.6
  • 16
    • 0030811665 scopus 로고    scopus 로고
    • Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia - A randomized phase-III study
    • Geissler K, Koller E, Hubmann E, Niederwieser D, Hinterberger W, Geissler D, et al. Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia-a randomized phase-III study. Blood 1997; 90: 590-6.
    • (1997) Blood , vol.90 , pp. 590-596
    • Geissler, K.1    Koller, E.2    Hubmann, E.3    Niederwieser, D.4    Hinterberger, W.5    Geissler, D.6
  • 17
    • 0030901774 scopus 로고    scopus 로고
    • Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia
    • Pui CH, Boyett JM, Hughes WT, Rivera GK, Hancock ML, Sandlund JT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997; 336: 1781-7.
    • (1997) N Engl J Med , vol.336 , pp. 1781-1787
    • Pui, C.H.1    Boyett, J.M.2    Hughes, W.T.3    Rivera, G.K.4    Hancock, M.L.5    Sandlund, J.T.6
  • 18
    • 0032170428 scopus 로고    scopus 로고
    • A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111
    • Larson RA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998; 92: 1556-64.
    • (1998) Blood , vol.92 , pp. 1556-1564
    • Larson, R.A.1    Dodge, R.K.2    Linker, C.A.3    Stone, R.M.4    Powell, B.L.5    Lee, E.J.6
  • 19
    • 0037842130 scopus 로고    scopus 로고
    • Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: A Children's Cancer Group Study
    • Heath JA, Steinherz PG, Altman A, Sather H, Jhanwar S, Halpern S, et al. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study. J Clin Oncol 2003; 21: 1612-7.
    • (2003) J Clin Oncol , vol.21 , pp. 1612-1617
    • Heath, J.A.1    Steinherz, P.G.2    Altman, A.3    Sather, H.4    Jhanwar, S.5    Halpern, S.6
  • 20
    • 0042967809 scopus 로고    scopus 로고
    • Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia
    • Lowenberg B, van Putten W, Theobald M, Gmur J, Verdonck L, Sonneveld P, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003; 349: 743-52.
    • (2003) N Engl J Med , vol.349 , pp. 743-752
    • Lowenberg, B.1    Van Putten, W.2    Theobald, M.3    Gmur, J.4    Verdonck, L.5    Sonneveld, P.6
  • 21
    • 0029068452 scopus 로고
    • A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia
    • AML Cooperative Study Group
    • Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med 1995; 332: 1678-83.
    • (1995) N Engl J Med , vol.332 , pp. 1678-1683
    • Dombret, H.1    Chastang, C.2    Fenaux, P.3    Reiffers, J.4    Bordessoule, D.5    Bouabdallah, R.6
  • 22
    • 0032525248 scopus 로고    scopus 로고
    • A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest oncology group study (9031)
    • Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 1998; 91: 3607-15.
    • (1998) Blood , vol.91 , pp. 3607-3615
    • Godwin, J.E.1    Kopecky, K.J.2    Head, D.R.3    Willman, C.L.4    Leith, C.P.5    Hynes, H.E.6
  • 23
    • 0033957073 scopus 로고    scopus 로고
    • Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: Results of a randomized trial of the Groupe Ouesr-Est Leucemies Aigues Myeloblastiques
    • Harousseau JL, Witz B, Lioure B, Hunault-Berger M, Desablens B, Delain M, et al. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouesr-Est Leucemies Aigues Myeloblastiques. J Clin Oncol 2000; 18: 780-7.
    • (2000) J Clin Oncol , vol.18 , pp. 780-787
    • Harousseau, J.L.1    Witz, B.2    Lioure, B.3    Hunault-Berger, M.4    Desablens, B.5    Delain, M.6
  • 24
    • 8944234342 scopus 로고    scopus 로고
    • Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group
    • Zittoun R, Suciu S, Mandelli F, de Witte T, Thaler J, Stryckmans P, et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1996; 14: 2150-9.
    • (1996) J Clin Oncol , vol.14 , pp. 2150-2159
    • Zittoun, R.1    Suciu, S.2    Mandelli, F.3    De Witte, T.4    Thaler, J.5    Stryckmans, P.6
  • 25
    • 6844251615 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia
    • The International Acute Myeloid Leukemia Study Group
    • Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997; 90: 4710-8.
    • (1997) Blood , vol.90 , pp. 4710-4718
    • Heil, G.1    Hoelzer, D.2    Sanz, M.A.3    Lechner, K.4    Liu Yin, J.A.5    Papa, G.6
  • 26
    • 0342460479 scopus 로고    scopus 로고
    • Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia
    • Lowenberg B, Boogaerts MA, Daenen SM, Verhoef GE, Hagenbeek A, Vellenga E, et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 1997; 15: 3496-506.
    • (1997) J Clin Oncol , vol.15 , pp. 3496-3506
    • Lowenberg, B.1    Boogaerts, M.A.2    Daenen, S.M.3    Verhoef, G.E.4    Hagenbeek, A.5    Vellenga, E.6
  • 27
    • 22044454414 scopus 로고    scopus 로고
    • Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: Final results of AML-13, a randomized phase-3 study
    • Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 2005; 106: 27-34.
    • (2005) Blood , vol.106 , pp. 27-34
    • Amadori, S.1    Suciu, S.2    Jehn, U.3    Stasi, R.4    Thomas, X.5    Marie, J.P.6
  • 29
    • 3142619150 scopus 로고    scopus 로고
    • Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: A randomized, controlled trial
    • Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarre MC, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004; 104: 321-7.
    • (2004) Blood , vol.104 , pp. 321-327
    • Casadevall, N.1    Durieux, P.2    Dubois, S.3    Hemery, F.4    Lepage, E.5    Quarre, M.C.6
  • 30
    • 0017165031 scopus 로고
    • Increase in circulating stem cells following chemotherapy in man
    • Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976; 47: 1031-9.
    • (1976) Blood , vol.47 , pp. 1031-1039
    • Richman, C.M.1    Weiner, R.S.2    Yankee, R.A.3
  • 31
    • 0021145267 scopus 로고
    • High levels of circulating haemopoietic stem cells in very early remission from acute non-lymphoblastic leukaemia and their collection and cryopreservation
    • To LB, Haylock DN, Kimber RJ, Juttner CA. High levels of circulating haemopoietic stem cells in very early remission from acute non-lymphoblastic leukaemia and their collection and cryopreservation. Br J Haematol 1984; 58: 399-410.
    • (1984) Br J Haematol , vol.58 , pp. 399-410
    • To, L.B.1    Haylock, D.N.2    Kimber, R.J.3    Juttner, C.A.4
  • 32
    • 10744227378 scopus 로고    scopus 로고
    • Differences between graft product and donor side effects following bone marrow or stem cell donation
    • Favre G, Beksac M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E, et al. Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplant 2003; 32: 873-80.
    • (2003) Bone Marrow Transplant , vol.32 , pp. 873-880
    • Favre, G.1    Beksac, M.2    Bacigalupo, A.3    Ruutu, T.4    Nagler, A.5    Gluckman, E.6
  • 33
    • 8844285963 scopus 로고    scopus 로고
    • Factors for PBPC collection efficiency and collection predictors
    • Ikeda K, Kozuka T, Harada M. Factors for PBPC collection efficiency and collection predictors. Transfus Apheresis Sci 2004; 31: 245-59.
    • (2004) Transfus Apheresis Sci , vol.31 , pp. 245-259
    • Ikeda, K.1    Kozuka, T.2    Harada, M.3
  • 34
    • 0026504705 scopus 로고
    • Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy
    • Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-4.
    • (1992) Lancet , vol.339 , pp. 640-644
    • Sheridan, W.P.1    Begley, C.G.2    Juttner, C.A.3    Szer, J.4    To, L.B.5    Maher, D.6
  • 35
    • 0028277465 scopus 로고
    • Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure
    • Maciejewski JP, Anderson S, Katevas P, Young NS. Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure. Br J Haematol 1994; 87: 227-34.
    • (1994) Br J Haematol , vol.87 , pp. 227-234
    • Maciejewski, J.P.1    Anderson, S.2    Katevas, P.3    Young, N.S.4
  • 36
    • 17644440714 scopus 로고    scopus 로고
    • Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: An update of the GITMO/EBMT study on 100 patients
    • European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO)
    • Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 2000; 95: 1931-4.
    • (2000) Blood , vol.95 , pp. 1931-1934
    • Bacigalupo, A.1    Bruno, B.2    Saracco, P.3    Di Bona, E.4    Locasciulli, A.5    Locatelli, F.6
  • 37
    • 4644343664 scopus 로고    scopus 로고
    • Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulating factor regimens: A GITMO prospective randomized study
    • Locasciulli A, Bruno B, Rambaldi A, Saracco P, Dufour C, Finelli C, et al. Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulating factor regimens: a GITMO prospective randomized study. Haematologica 2004; 89: 1054-61.
    • (2004) Haematologica , vol.89 , pp. 1054-1061
    • Locasciulli, A.1    Bruno, B.2    Rambaldi, A.3    Saracco, P.4    Dufour, C.5    Finelli, C.6
  • 38
    • 0036682934 scopus 로고    scopus 로고
    • Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children
    • Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y, et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood 2002; 100: 786-90.
    • (2002) Blood , vol.100 , pp. 786-790
    • Kojima, S.1    Ohara, A.2    Tsuchida, M.3    Kudoh, T.4    Hanada, R.5    Okimoto, Y.6
  • 39
    • 12244255076 scopus 로고    scopus 로고
    • Severe chronic neutropenia: Treatment and follow-up of the Severe Chronic Neutropenia International Registry
    • Dale DC, Cottle TE, Fier CJ, Bolyard AA, Bonilla MA. Severe chronic neutropenia: treatment and follow-up of the Severe Chronic Neutropenia International Registry. Am J Hematol 2003; 72: 82-93.
    • (2003) Am J Hematol , vol.72 , pp. 82-93
    • Dale, D.C.1    Cottle, T.E.2    Fier, C.J.3    Bolyard, A.A.4    Bonilla, M.A.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.